While conventionally known for its function as an inhibitory neurotransmitter, GABA signaling was recently discovered to have a significant role in fate determination of blood stem cells.
KRAS mutations drive roughly a quarter of all human cancers, yet approved KRAS inhibitors deliver only short-lived responses before resistance emerges, and combination strategies have been limited by severe toxicity.
Stanford researchers have developed a next-generation programmable transcriptional activation platform, TIGRa, that addresses key limitations of CRISPRa technologies, including large size, limited multiplexing capacity, and delivery constraints.
Stanford University researchers in the Bamm and Durmus Labs have developed the Dynamic AI-Driven Raman Techniques (DART) platform, which integrates electrochemical enhancement with surface-enhanced Raman spectroscopy for real-time, sensitive, specific, reproducible biomarker d
Stanford researchers have developed a new therapeutic approach to protect neurons and promote axon regeneration by restoring mitochondrial transport within axons, a key process disrupted in many neurodegenerative diseases.
Stanford scientists have discovered a novel approach to address cardiovascular complications resulting from cancer chemotherapy, particularly those caused by tyrosine kinase inhibitors (TKIs).
Systemic chemotherapy remains the main treatment option for malignant tumors, including breast cancer. Nevertheless, the frequent development of resistance in tumors often causes treatment failure and patient death, presenting a significant challenge in cancer treatment.
Researchers at Stanford have developed compounds for inhibiting the epidermal growth factor receptor (EGFR) that covalently label a nucleophile that has not been targeted before.
Researchers at Stanford have developed a novel method of using macrocyclic compounds that act as inhibitors of epidermal growth factor receptor (EGFR) for the treatment or prevention of kinase-mediated disorders, including cancer and other proliferation diseases.
Glaucoma results from the loss of retinal ganglion cells (RGCs), the primary output neurons of the retina that connect to brain areas responsible for vision. Current treatments focus on lowering intraocular pressure but do not prevent blindness in about 25% of patients.
High-grade gliomas, such as glioblastoma and diffuse midline glioma, are currently incurable diseases with an urgent need for novel therapeutic approaches.
Stanford researchers have developed REULR (Receptor Elimination by E3 Ubiquitin Ligase Recruitment), a mix and match nanobody (VHH)-based extracellular targeted protein degradation (eTPD) platform.
Stanford researchers have found that inhibiting 15-prostaglandin dehydrogenase (15-PGDH), which breaks down prostaglandin E2 (PGE2), can improve cardiac function in diseased and aged hearts.